# Johnson & Johnson (JNJ) Stock Analysis: Is the Healthcare Giant a Buy with Its Solid Dividend Yield?

- Link: https://www.directorstalkinterviews.com/johnson-johnson-jnj-stock-analysis-is-the-healthcare-giant-a-buy-with-its-solid-dividend-yield/4121214297
- Published: 2025-09-01T10:02:45+01:00
- Author: Madison Wilson

Johnson & Johnson (NYSE: JNJ), a stalwart in the healthcare sector, has long been
a favorite among investors for its robust product portfolio and consistent dividend
payouts. With a market capitalization of $426.69 billion, JNJ stands as a cornerstone
of the drug manufacturers industry, offering a wide range of products through its
Innovative Medicine and MedTech segments.

As of the latest trading session, JNJ’s stock price hovers at $177.17, just below
its 52-week high of $179.29. Despite a modest price change of 0.01%, the stock has
shown resilience, maintaining a steady trajectory over the past year. However, the
current price slightly exceeds the average analyst target of $176.60, suggesting
a potential downside of -0.32%.

Valuation metrics present a mixed picture. While the trailing P/E ratio is not available,
the forward P/E stands at 15.59, indicating that the market anticipates steady earnings
growth. The absence of PEG, Price/Book, Price/Sales, and EV/EBITDA ratios necessitates
a deeper dive into the company’s profitability and cash flow metrics. Notably, Johnson&
Johnson boasts a robust EPS of 9.34 and a commendable return on equity of 30.21%,
underscoring its ability to generate substantial returns from shareholders’ equity.

The company has demonstrated a healthy revenue growth rate of 5.80%, complemented
by a formidable free cash flow of approximately $11.08 billion. For income-focused
investors, Johnson & Johnson’s dividend yield of 2.94% is particularly appealing,
supported by a payout ratio of 53.75%, pointing to a sustainable dividend policy.

Analyzing its technical indicators, JNJ’s stock currently trades above its 50-day
moving average of $165.87 and 200-day moving average of $156.98, suggesting a bullish
momentum. However, the Relative Strength Index (RSI) at 37.04 signals that the stock
is approaching oversold territory, which could entice value investors looking for
entry points.

Analyst ratings reveal a consensus leaning towards a hold, with 10 buy ratings, 
14 hold ratings, and no sell ratings. The target price range between $155.00 and
$200.00 reflects varied opinions on the stock’s future trajectory, but the absence
of sell ratings showcases confidence in the company’s stability and growth prospects.

Johnson & Johnson’s diverse portfolio, spanning from immunology and oncology to 
MedTech solutions in orthopaedics and surgical technologies, provides a solid foundation
for long-term growth. The company, founded in 1886 and headquartered in New Brunswick,
New Jersey, continues to innovate and expand its market reach globally.

For investors seeking a reliable player in the healthcare sector, Johnson & Johnson’s
combination of consistent dividend payouts, strong cash flow, and strategic market
position makes it a compelling consideration. However, potential investors should
weigh these strengths against the current valuation and market dynamics to determine
if JNJ aligns with their investment goals.

Share on:
